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Abstract
Background: Matrix metalloproteinases are important factors in the molecular mechanisms leading to neuronal injury
in many neurological disorders. Matrix metalloproteinase (MMP)-9 is up-regulated after cerebral ischemia and
neuroinflammation and is actively involved in blood–brain barrier disruption. Current methods of measuring MMP-9
activity, such as gelatin-substrate zymography, are unspecific and arduous. Here we developed an immunocapture
assay with high efficiency, specificity, and sensitivity for quantifying endogenously active as well as total MMP-9 activity.
Results: A fluorescence resonance energy transfer (FRET) peptide-based immunocapture assay was developed that
enables the accurate assessment of total and active forms of MMP-9 in complex biological samples. The FRET assay
demonstrated correct and efficient binding of MMP-9 to a mouse monoclonal MMP-9 antibody and high specificity of
the immunocapture antibody for MMP-9. Total and active levels of MMP-9 were measured in rat brain homogenates,
plasma, human HT-1080 conditioned media, and RBE4 endothelial cell lysates. The FRET immunocapture assay yielded
highly similar results for total MMP-9 activity when compared to gelatin-substrate zymography.
Conclusions: We suggest that the new FRET peptide-based immunocapture assay is a viable replacement of
zymography for sensitive and high throughput quantification of MMP-9 activity in biological samples.
Keywords: Matrix metalloproteinase-9 activity, Fluorescence resonance energy transfer peptide, Immunocapture assay,
Focal cerebral ischemia
Background
Matrix metalloproteinases (MMPs) are a family of 23
members of calcium- and zinc-dependent endopepti-
dases with the ability to degrade extracellular matrix
(ECM) proteins, including collagen, fibronectin, laminin,
elastin, and proteoglycans [1-4]. The MMPs are widely
studied due to their involvement in several human
diseases including cancer, osteoarthritis, inflammation,
neurodegeneration, and cerebrovascular diseases.
MMPs are produced as a zymogen (latent pro-MMP
devoid of enzymatic activity), but upon activation, they
participate in many physiological as well as pathological
events. The pro-domain (pro-MMP) contains a cysteine
residue that acts as a zinc-coordinating ligand masking
the catalytic domain of the protease (‘cysteine switch’)
and preventing the zinc atom in the catalytic domain
from being available for enzymatic function [5]. Proteo-
lytic cleavage of the pro-domain by proteases (including
other MMPs) [6,7], oxidative modifications of the thiol
group on the zinc-binding cysteine (e.g., S-nitrosylation)
[8-10], or conformational changes due to substrate
binding [11] result in the activation of the MMP.
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Among the MMPs, the gelatinases (MMP-2 and
MMP-9) as well as MMP-3 (stromelysin-1) and MMP-
13 (collagenase-3) have been recognized as key players
in the molecular mechanisms leading to neuronal injury
in neurodegenerative conditions, traumatic brain injury,
meningitis, multiple sclerosis, and stroke [4,12-15]. Dam-
age to the blood–brain barrier (BBB) is a well-established
neuropathological mechanism following brain injury, and
activation of MMPs is critical in BBB breakdown under
these conditions. Brain edema, hemorrhage, and neuronal
death are the main consequences of BBB disruption
following brain damage.
MMP-9 (gelatinase B) is significantly upregulated in
animal models of cerebral ischemia [16-21], traumatic
brain injury [22-26], and neuroinflammation [27-29]. A
large body of evidence strongly implicates MMP-9 in the
detrimental molecular cascades leading to BBB dysfunc-
tion in these conditions. In stroke, MMP-9 plays a prin-
cipal role in hemorrhagic conversion and vasogenic
edema in animal models [16,19,21,30-34] and stroke
patients [35-40]. Severe neurological deficits and brain
tissue loss positively correlate with elevated MMP-9
levels in stroke patients, who are at higher risk for deve-
loping life-threatening cerebral edema and hemorrhage
[35,37,38,41-46].
Gelatin-substrate zymography is extensively used for
the detection of gelatinase activity (MMP-2 and MMP-9)
in biological samples [1]. This electrophoretic method-
ology is simple to perform and relatively sensitive, but
may demand arduous work when a large number of sam-
ples need to be tested. A shortcoming of zymography is
that it only provides a measure of total MMP-2/-9 expres-
sion (pro-MMPs plus active MMPs). Identification of
active forms of these proteases in the gels is not always
possible because of the low levels of expression, making
net levels of activity for each gelatinase difficult to accur-
ately quantify [47]. In addition, assessment of MMP-2/-9
expression in gelatin zymograms by quantifying active
bands migrating at lower molecular weight might under-
estimate MMP activity since it has been shown that
pro-MMPs could be activated by oxidative stress without
proteolytic cleavage. This type of activation process does
not appreciably change their molecular weight [9,48].
The majority of MMP-9 is in a latent form, but it is
the active form that exerts biological activity. Specific
peptide substrates for MMP-9, and in general for any par-
ticular MMP, are very difficult to design because most
MMPs share proteolytic recognition sequences [47,49-53].
Two methods have been described to specifically detect
MMP activity in complex biological samples. Both use an
immunocapture antibody to first immobilize the specific
MMP to a 96-well plate followed by monitoring of the
proteolytic activity using chromogenic or fluorogenic pep-
tides [49,54].
Based on these previously reported methods, here we
describe the development of a high-throughput and
highly sensitive MMP-9 activity assay able to detect
endogenously active MMP-9 in biological samples. One
of the main modifications in our assay is the initial coat-
ing of the plate with protein A/G and the use of a highly
sensitive fluorescence resonance energy transfer (FRET)
peptide substrate for MMP-9. By using protein A/G,
which binds to the Fc region of immunoglobulins, we
are able to immobilize and correctly orient the antibody
for maximum MMP-9 immunocapture. This critical step
in our methodology results in a more efficient and
correct binding of the antibody to the plate compared to
immobilization by passive absorption. The use of a
commercially available FRET peptide having 5-carboxy
-fluorescein (5-FAM) as a donor is another important
improvement in our assay yielding a very strong fluores-
cent signal upon cleavage of the peptide by MMP-9. The
use of other FRET pairs for measuring MMP activity
have been proven to yield low fluorescence signals and
consequently less sensitivity compared to 5-FAM pep-
tides [55].
The general principle of our assay is presented in
Figure 1. We validated this novel assay in complex bio-
logical matrices including rat brain homogenates, plasma,
cell culture media from HT-1080 cancer cells, and RBE4
endothelial cell lysates. This sensitive fluorometric immu-
nocapture assay specific for MMP-9 could be widely
utilized to quantify active MMP-9 in biological samples
and should be considered as a replacement for gelatin-
based zymography. By changing the immunocapture anti-
body and FRET peptide, the activity of other members of
the MMP family could be measured.
Results and discussion
Rat and human MMP-9 specifically and efficiently binds
to mouse monoclonal anti-MMP-9
We first needed to determine the efficacy of the immu-
nocapture antibody. The dose response of the mouse
monoclonal anti-MMP-9 to rat and human recombinant
MMP-9 (0.5, 1.0, 2.5, 5.0, and 10 ng) was examined
(Figure 2A and 2B). Both rat and human MMP-9 fluores-
cent activity (measured in relative fluorescent units, or
RFUs) increased as the quantity of recombinant MMP-9
increased. Figures 2C and 2D demonstrate the activity of
“free” (no antibody coating on the plate, MMP-9 is added
directly to the plate) versus immunocaptured rat and
human MMP-9 (5 ng). No significant binding interference
with the activity or activation of the gelatinase was ob-
served with rat or human recombinant MMP-9. These
findings indicate that binding of MMP-9 to the antibody
is highly efficient as binding does not significantly reduce
the catalytic ability of MMP-9.
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A significant advantage in our methodology is to coat
the black 96-well plate with protein G or use commer-
cially available protein G coated plates. A more efficient
immobilization of the anti-MMP-9 antibody to the plate
results in a better sensitivity as shown in the Additional
file 1: Figure S1. We compared the RFUs values for three
different concentrations of active human recombinant
MMP-9 between plates that were initially coated with
protein G and non-coated plates. In the non-coated plates,
the anti-MMP-9 antibody was immobilized by passive
absorption to Fluotrac 600 high-binding plates overnight
at 4°C. As presented in the Additional file 1: Figure S1,
MMP-9 activity was significantly higher (p < 0.01) when
the immunocapture antibody was immobilized to protein
G-coated plates compared to plates in which the antibody
was immobilized by passive absorption.
To study the specificity of the antibody for MMP-9,
we assessed cross-reactivity with MMP-2. Because
MMP-9 and MMP-2 have structural similarities, it was
possible that MMP-2 binding and activation could con-
tribute to the observed fluorescence. When recombinant
rat MMP-2 was immunocaptured with the MMP-9 anti-
body, no detectable activity was observed (Figure 2E).
This indicates rat MMP-2 is not recognized and
captured by the MMP-9 antibody and is likely removed
during a washing step. Recombinant human MMP-2
was immunocaptured at barely detectable activity levels,
which indicates that human MMP-2, at very high doses,
either will bind to the anti-MMP-9 or can bind to the
protein G on the plate. However, the binding of human
MMP-2 is probably not competitive with MMP-9
binding in biological samples. Rat and human MMP-2,
pre-activated with APMA, was added to a plate with no
antibody and combined with the FRET peptide. The free-
floating MMP-2 (5 and 10 ng) was then able to interact
with the FRET peptide to produce fluorescence (Figure 2E
and 2F). This indicates that the lack of fluorescence when
MMP-2 was immunocaptured with the mouse anti-MMP
-9 is not due to lack of activity of the recombinant MMP-
2. Specificity of the MMP-9 antibody for rat and human
MMP-9 but not for rat or human MMP-2 was further
demonstrated via immunoblotting (Figure 2G). Rat and
human MMP-9 and MMP-2 were loaded in the gels.
Initially, only MMP-9 was probed for using the mouse
anti-MMP-9 antibody (shown in green). No bands were
detected in the MMP-2 lanes, indicating that monoclonal
MMP-9 antibody does not recognize rat or human MMP-
2. To confirm the presence of MMP-2 in the gels, a sec-
ond probe using an anti-MMP-2 antibody was performed
(shown in red). These data indicate the monoclonal
mouse antibody is highly specific for MMP-9.
Total and endogenously active levels of MMP-9 are
measurable with the FRET peptide-based immunocapture
assay in multiple biological samples
For this assay to be a viable technology in many research
laboratories, it must be able to detect MMP-9 levels in













-5-FAM QXL™520- -5-FAMFRET peptide
Figure 1 FRET peptide-based immunocapture assay for MMP-9. Mouse monoclonal anti-MMP-9 was added to a 96-well plate coated in
Protein G to facilitate binding to the Fc region of the antibody, thus leaving the Fab region in an optimal orientation for tightly binding MMP-9.
After incubation with the antibody, biological samples containing both active and pro-MMP-9 were added to the plate and allowed to incubate
with the antibody to facilitate tight binding. In experiments that required activation of pro-MMP-9 to quantify total levels, APMA is added to
activate the pro-MMP-9. Intact FRET peptide, in which the QXL™520 fragment is quenching the fluorescence of the 5-FAM donor, is added to the
wells. Catalytically active MMP-9 is able to cleave the FRET peptide, allowing the fluorescent 5-FAM fragment to be read and monitored at
excitation/emission wavelengths of 485/528 nm.
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Figure 2 Rat and human MMP-9 specifically and efficiently binds to mouse monoclonal anti-MMP-9. Recombinant MMP-9 activity and
specificity was measured. (A) Dose response of rat and (B) human recombinant MMP-9 was determined (n = 3–5). (C) Activity of free versus
immunocaptured rat and (D) human MMP-9. Free MMP-9 was not bound to the MMP-9 antibody but instead was free-floating. Rat and human
free vs. immunocaptured MMP-9 activity did not differ (p > 0.05, n = 4). All relative fluorescent units were normalized to a substrate control with
0 ng MMP-9. (E) Rat and (F) human recombinant MMP-2 was incubated with or without antibody to check the specificity of the MMP-9 antibody.
No signal was detected with rat MMP-2 and very little signal was detected with human MMP-2 in the immunocapturing condition whereas free
active MMP-2 did have fluorescent activity (n = 2–3). (G) Immunoblot for anti-MMP-9 specificity to MMP-9. Rat and human recombinant MMP-9
(92 kDa) and MMP-2 (72 kDa) were probed with the mouse monoclonal anti-MMP-9 then detected with a secondary antibody against mouse (in
green). To confirm presence of MMP-2, an anti-MMP-2 antibody was used and counterstained (in red). 10 ng of rat MMP-9 was not enough
protein to have significant binding with the MMP-9 antibody.
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of the assay to detect both total and endogenously active
levels of MMP-9 in homogenates of rat cerebral cortex
and plasma obtained from animals subjected to transient
focal cerebral ischemia by middle cerebral artery occlusion
(MCAO). Total and endogenously active levels of MMP-9
were recorded in ipsilateral (same hemisphere as ische-
mia) and contralateral (opposite hemisphere from ische-
mia) samples with 500 μg total protein (Figure 3A).
Ipsilateral samples had more activity compared to contra-
lateral samples for both total and active MMP-9. The
addition of a classic matrix metalloproteinase inhibitor,
GM6001 (total concentration 10 μM), to ipsilateral
samples greatly reduced the activity of MMP-9. We have
successfully detected total and endogenously active levels
of MMP-9 in rat brain homogenates using as low as 50 μg
total protein which emphasizes the high sensitivity of the
assay (data not shown).
Figure 3B shows MMP-9 activity in 50 μL of rat
plasma samples from sham-operated rats (surgery but
no occlusion of the middle cerebral artery) and MCAO
rats. Plasma from the sham rats had significantly less
total MMP-9 activity than MCAO rats. Again, with the
addition of GM6001 (10 μM) to the MCAO rat plasma,
there was a large reduction in the activity of MMP-9.
We also used the gelatinase inhibitor SB-3CT (0.5 μM
and 5.0 μM) to check the specificity of the inhibition of
MMP-9 in the plasma samples, as SB-3CT has very high
selectivity to MMP-2 and MMP-9 compared to GM6001
[56,57]. When SB-3CT was added to the MCAO plasma
samples, there was a significant decrease in MMP-9
activity dependent on the concentration of SB-3CT
added (Figure 3C).
This assay can also detect levels of human MMP-9 in
conditioned cell culture media. As Figure 3D illustrates,
increasing amounts of conditioned media (10, 50, and
100 μL) from the human fibrosarcoma cell line HT-1080,
when immunocaptured with the mouse anti-MMP-9,
coincides with greater MMP-9 activity.
Rat brain endothelial 4 (RBE4) cells are known to
respond to inflammatory stimuli such as IL-1β [58]. We
tested whether levels of MMP-9 can also be ascertained
in cell lysates. Lysates were taken from RBE4 cells that
were subjected to 24 h of stimulation with interleukin-
1β (IL-1β; 10 ng/mL). When compared to control cell
lysates, levels of MMP-9 in lysates from treated cells
were significantly increased as seen by gelatin-substrate
zymography (Figure 3E and 3F). When measured with
the new FRET peptide assay, IL-1β-treated cell lysates
had significantly more MMP-9 activity than controls
(Figure 3G), indicating that this new assay demonstrates
a similar trend in the MMP-9 levels in RBE4 cells after
treatment with IL-1β as zymography.
Following ischemia/reperfusion, levels of MMP-9 are
dramatically increased in the brain, specifically the
ipsilateral hemisphere [32,40]. Our FRET peptide-based
assay reflects this well-known biological response and is
sensitive enough to measure only endogenously active
MMP-9 in samples, unlike zymography which primarily
measures total levels of MMP-9. MMP-9 that is acti-
vated by oxidative stress is more easily quantified in this
assay method as well, since activating pro-MMP-9 in
this way does not substantially alter the molecular
weight of MMP-9, therefore making it difficult to distin-
guish from the pro-MMP-9 in a zymogram. Inhibition of
MMP-9 proteolytic activity by adding GM6001 to brain
tissue, and GM6001 as well as SB-3CT in rat plasma,
greatly reduced the emitted fluorescence, indicating it is
MMP-9 cleaving the FRET peptide and not a different
protease. That this assay also works in cultured cell
media and cell lysates indicates it is not limited in sam-
ple medium as it can assess MMP-9 levels in multiple
biological samples.
MMP-9 activity correlates in gelatin-substrate
zymography and FRET peptide-based immunocapture
assay
Gelatin-substrate zymography is a popular and accepted
method for measuring levels of MMP-2/-9 in samples.
However, if large amounts of samples need to be tested,
repeated zymography can be very time-consuming. For
all of this effort, only total levels of MMP-2/-9 can be
accurately detected rather than both active and total levels
of the gelatinases. Our proposed FRET peptide-based
immunocapture assay provides the ability for many sam-
ples to be tested at once while also allowing for a choice
of total or endogenously active levels of MMP-9 to be
quantified. For this assay to be a viable replacement of
gelatin-substrate zymography, relative fluorescence units
(RFUs) observed for a sample in the immunocapture assay
must be similar to relative lysis units (RLUs) recorded
from gelatin zymography. To check for this correlation,
total MMP-9 levels were studied from 16 rat MCAO
cerebral cortex homogenates (ipsilateral and contralateral)
in both the immunocapture assay and gelatin-substrate
zymography. A sample zymogram of rat cortex samples
and HT-1080 conditioned media indicating both gela-
tinases is shown in Figure 4A. As seen in the FRET
peptide assay (Figure 3A), the zymogram data illustrates
MMP-9 activity in ipsilateral samples as greater than
contralateral samples. To determine whether the data
from each method are comparable, we plotted the RLUs
from the zymograms against the RFUs obtained from the
FRET assay (Figure 4B). Total MMP-9 activity levels
highly correlate between the two methods, indicating
MMP-9 activity reported from zymography is very similar
to that determined from the FRET peptide-based assay.
These data indicate that the FRET-based immunocapture
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Figure 3 Total and endogenously active MMP-9 are measurable with the FRET peptide-based immunocapture assay in multiple
biological samples. Brain homogenates and plasma obtained from rats that underwent MCAO and sacrificed 48 h later were used in the new
FRET peptide assay. (A) Total and active MMP-9 activity was measured in 500 μg total protein from ipsilateral and contralateral cerebral cortex.
GM6001 (10 μM) was added to total MMP-9 ipsilateral samples. Total ipsilateral, active ipsilateral, and total ipsilateral + GM6001 compared by
ANOVA with Newman-Keuls post-hoc test. * Statistically significant decreases compared to ipsilateral, p < 0.001, n = 7–8. # Statistically significant
decrease compared to total ipsilateral, p < 0.01, n = 4–8. (B) Total MMP-9 activity recorded from 50 μL plasma from sham and MCAO rats.
GM6001 (10 μM) added to MCAO plasma samples significantly reduced MMP-9 activity. Compared by ANOVA with Newman-Keuls post-hoc test.
** Statistically significant difference compared to MCAO, p < 0.001, n = 5. (C) Total MMP-9 activity from MCAO rat plasma samples (50 μL) and
MCAO with the gelatinase inhibitor SB-3CT (0.5 μM and 5.0 μM). MMP-9 activity was significantly reduced with addition of SB-3CT in a dose-
dependent manner. Compared by ANOVA with Newman-Keuls post-hoc test. *** Significant decrease compared to MCAO, p < 0.0001, n = 5. (D)
Total MMP-9 activity in 10, 50, and 100 μL HT-1080 conditioned media (n = 4–6). (E) Zymogram, (F) densitometric analysis, and (G) FRET assay of
total MMP-9 activity in lysates from RBE4 cells treated with IL-1β (10 ng/mL) compared to controls. Treatment with IL-1β significantly increased
total MMP-9 levels in RBE4 cells as seen with zymography (Student’s t-test, * p < 0.05, n = 3) and the FRET assay (Student’s t-test, * p < 0.05, n = 3
independent experiments).
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assay is a possible quantitative replacement of gelatin
zymography for measurement of MMP-9.
Another advantage of the FRET-based assay is the
flexibility offered. Other MMPs can easily be measured
by altering the specific immunocapture antibody and/or
the FRET peptide used. While gelatin zymography is
limited to measurement of only total MMP-2 and MMP-9
activity, the FRET peptide assay can quantify total and
active levels of the gelatinases.
Conclusion
Gelatin-substrate zymography is the go-to method for
measurement of gelatinase activity in samples despite
lengthy experiment times and restrictions on observable
data. A new method, the FRET peptide-based immuno-
capture assay, has increased throughput, flexibility, and




The protein G coated 96-well plates and the mouse mono-
clonal anti-MMP-9 antibody were purchased from Thermo
Fisher Scientific (Cat. Nos. 15157 and MS-817-P, respect-
ively; Rockford, IL, USA). The FRET peptide was purchased
from AnaSpec (Cat. No. 60570–01; San Jose, CA, USA).
4-aminophenylmercuric acetate (APMA), GM6001, and
SB-3CT were purchased from Sigma-Aldrich (Cat. Nos.
A9563-5G, M5939, and S1326, respectively; St. Louis,
MO, USA).
Rat and human recombinant MMP-9 were purchased
from R&D Systems (Cat. Nos. 5427-MM and 911-MP-010;
Minneapolis, MN, USA). Rat and human recombinant
MMP-2 were purchased from Abcam (Cat. Nos. ab39304
and ab40964; Cambridge, MA, USA). Crude brain tissue
homogenates were prepared from rats with right side focal
ischemia. Unfixed frozen cortex samples from both the
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Figure 4 MMP-9 activity correlates in gelatin-substrate zymography and FRET peptide-based immunocapture assay. Results of MMP-9
activity from rat MCAO brain tissue homogenate samples were compared between zymography and the FRET immunocapture assay. (A)
Representative zymogram of 50 μg total protein from rat cerebral cortex homogenates, ipsilateral (ipsi) and contralateral (contra) hemispheres,
and HT-1080 conditioned media. MMP-9 (94 and 88 kDa) and MMP-2 (72 kDa) are shown. Quantification of MMP-9 included the 94 and 88 kDa
bands. (B) Correlation of relative lysis units (RLUs) quantified from zymography and relative fluorescent units (RFUs) recorded from the FRET
peptide-based assay from 16 rat ipsilateral and 16 rat contralateral cerebral cortex samples. Compared with linear regression analysis, R2 = 0.8024,
p < 0.0001, n = 32.
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ipsilateral and contralateral hemispheres were weighed and
homogenized in 1% sodium dodecyl sulfate (SDS) buffer
containing 150 mM NaCl, 50 mM Tris–HCl pH 7.6, 1%
IGEPALW CA-630, and 1% sodium deoxycholate. Just
before the buffer was added to the brain samples, HALT
Protease Inhibitor Cocktail (Cat. No. 78430; Thermo Fisher
Scientific), HALT Phosphatase Inhibitor cocktail (Cat. No.
78428; Thermo Fisher Scientific) and 0.5 M EDTA were
added at 10 μL/mL of homogenization buffer. Chilled
tissue was homogenized in the buffer for 15-20 s using a
Tissue-Tearor homogenizer (Cat. No. 985370; BioSpec,
Inc, Bartlesville, OK, USA) then sonicated twice using a
Vibra-Cell™ sonicator (Model VCX130PB; Sonics & Mate-
rials, Inc, Newtown, CT, USA). Resulting tissue homoge-
nates were centrifuged at 14,000 xg for 20 min at 4°C in an
Eppendorf microcentrifuge Model 5430R, and the superna-
tants aliquoted and stored at −80°C until used.
Rat stroke model and sample preparation
Focal cerebral ischemia was induced by temporary
middle cerebral artery occlusion (MCAO) in male Wistar
rats (280–320 g; Harlan Laboratories, Indianapolis, IN,
USA) using the intraluminal filament method as described
previously by our group [32,59]. Briefly, rats were anes-
thetized with isoflurane in medical-grade oxygen and a
midline vertical incision was made in the neck to expose
the common carotid artery (CCA), external carotid artery
(ECA) and internal carotid artery (ICA). The CCA was
ligated permanently with a 4–0 silk suture and a vascular
clip was temporarily placed in the pterygopalatine artery
to prevent incorrect insertion of the occluding filament. A
loose tie was placed over the ICA and ECA bifurcation
with 4–0 silk suture and vascular clips were placed in the
ICA and ECA. A small arteriotomy was made in the CCA
approximately 2 mm proximal to the carotid bifurcation.
A 4–0 silicone-coated filament (Cat. No. 403523PK10;
Doccol Corporation, Sharon, MA, USA) was inserted
through the CCA and advanced 18–20 mm inside the
ICA until a mild resistance was felt. The occluding
filament was left in place for 90 min and animals were
allowed to recover from anesthesia. Eight to ten minutes
before the end of the occlusion period, animals were re-
anesthetized with isoflurane inhalant anesthesia, and the
filament was gently retracted to allow reperfusion of the
MCA territory.
After 48 h of reperfusion, animals were deeply anes-
thetized with pentobarbital (150 mg/kg; i.p.) and a blood
sample was withdrawn from the vena cava into a hepa-
rinized syringe. Blood (1.5 mL) was quickly mixed with
50 μL of heparin (1000 U/mL) and centrifuged for 10 min
at 2,000 xg to obtain the plasma. Rats were perfused intra-
cardially with ice-cold saline and brains were harvested
and dissected into ipsilateral (stroke side) and contralateral
cerebral cortex and striatum. Samples were immediately
frozen on dry ice and stored at −80°C until use.
Cell culture
HT-1080 human fibrosarcoma cells were obtained from
American Type Culture Collection (ATCC, Manassas,
VA, USA) and maintained in DMEM:F12 medium (Life
Technologies, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (FBS; Cat. No. 10082–147; Life
Technologies), 100 U/mL penicillin and 100 μg/mL
streptomycin in a humidified incubator at 37°C and 5%
CO2. At 80-85% confluency, cells were washed with
Dulbecco’s PBS and fresh media without FBS was added.
After 24 h, cell culture media was collected and spun
down at 5,000 xg for 10 min at 4°C. Aliquots of the
HT-1080 conditioned media were prepared and stored
at −80°C until use.
Rat brain endothelial (RBE4) cells were cultured in
alpha-MEM/Ham’s F-10 Nutrient (1:1 solution; Cat.
Nos. 12571–063 and 11550–043; GIBCO, Life Techno-
logies) supplemented with 10% heat-inactivated fetal
bovine serum (Cat. No. F4135; Sigma), 1% penicillin/
streptomycin (Cat. No. 15140–122; GIBCO, Life Technolo-
gies), and 1% Geneticin (300 μg/mL; Cat. No. ALX-380
-013-G001; Enzo Life Sciences). RBE4 cells were seeded in
rat tail collagen I (50 μg/mL; Cat. No. C3867; Sigma)
coated 6-well plates (20,000-30,000 cells/cm2) and main-
tained at 37°C, 5% CO2 incubator for 2 days before treat-
ment. When cells reached 80-90% confluency, IL-1β
(10 ng/mL; Cat. No. 501-RL/CF; R&D Systems, Inc.,
Minneapolis, MN, USA) was added to wells as treated
groups. After 24 hours incubation, untreated and treated
cells were washed once with ice-cold phosphate-buffered
saline (PBS), and then lysed in radioimmunoprecipitation
(RIPA) buffer consisting of 50 mM Tris–HCl (pH 7.6), 150
mM NaCl, 1% NP-40, 1% Sodium deoxycholate and 1%
SDS plus complete protease and phosphatase inhibitor
cocktails (Cat. No. 78430 and 78428; Thermo Scientific).
Finally, the lysates were spun down at 14,000 xg for 15 min
at 4°C. Aliquots of the supernatants were saved and stored
at −80°C until use.
Immunocapture assay and fluorometric measurement of
MMP-9 enzymatic activity
The activity of MMP-9 in rat stroke brain samples was
measured fluorometrically using 5-FAM/QXL™520 FRET
peptide (Cat. No. 60570; AnaSpec, San Jose, CA). In the
intact FRET peptide (QXL™520-Pro-Leu-Gly-Cys[Me]-
His-Ala-D-Arg-Lys[5-FAM]-NH2), the fluorescence of
5-FAM (5-carboxy-fluorescein) is quenched by the prox-
imity of QXL™520. Upon cleavage into two fragments by
MMP-9, the fluorescence of 5-FAM can be read and
monitored at excitation/emission wavelengths of 485/
528 nm.
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Samples were prepared in 100 μL of TCNB buffer
(50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij
W
L23). Pierce protein G coated 96-well plates were
washed three times with 200 μL TCNB buffer. Mouse
monoclonal anti-MMP-9 (1 μg) in 100 μL of TCNB
buffer was added to the wells and incubated for two
hours at room temperature in a microplate mixer (USA
Scientific, Ocala, FL, USA). Plates were then washed
three times with 200 μL TCNB buffer and 100 μL of the
samples were added to the wells in duplicate and
allowed to incubate overnight at 4°C in a microplate
mixer. After washing the plates three times with TCNB
buffer, 1 mM APMA in 100 μL assay buffer (50 mM
Tris–HCl pH 7.6, 200 mM NaCl, 5 mM CaCl2, 20 μM
ZnCl, and 0.05% BrijW L23) was added to the wells to ac-
tivate pro-MMP-9 in the samples to detect total levels of
MMP-9, then covered in aluminum foil and incubated
for 90 min at 37°C. To detect only endogenously active
levels of MMP-9, APMA was not added and only 100
μL assay buffer was added to the wells. Next, 100 μL of
assay buffer with 2 μM FRET peptide was added to the
wells to bring total FRET peptide concentration to
1 μM. Fluorescence (relative fluorescence units, RFUs)
was measured after 24 h of incubation at 37°C at
485 nm excitation and 528 nm emission in a Synergy
HT Multi-mode microplate fluorescence reader (BioTek,
Winooski, VT, USA) running Gen5™ data analysis soft-
ware. A substrate control well was used to subtract base-
line fluorescence from the sample wells.
Fluorometric MMP-2/-9 activity measurement without
immunocapture
Recombinant MMPs were activated by adding APMA
for a final concentration of 1 mM and incubated for
90 min at 37°C. Active MMPs were prepared in 100 μL
assay buffer and mixed with 2 μM FRET peptide in 100
μL assay buffer for a final FRET peptide concentration of
1 μM. Fluorescence was monitored after a 24 h incubation
period at 37°C at the same wavelengths mentioned above.
Gelatin-substrate zymography
Substrate-specific zymography for determination of ac-
tivity of MMP-2 and MMP-9 was done on brain homog-
enates, HT-1080 conditioned media, and RBE4 cell
lysates as described before [27,60]. Brain homogenates
or RBE4 cell lysates (50 μg total protein) were mixed in
10 μL zymogram sample buffer (Cat. No. 161–0764; Bio-
Rad, Hercules, CA). 15 μL of HT-1080 conditioned
media at 1:10 dilution in zymogram sample buffer was
loaded in the gels. Proteins were separated by electro-
phoresis in a SDS-PAGE gel (8%) containing 0.1% (w/v)
gelatin (Cat. No. G-2500; Sigma-Aldrich) at 150 V
constant voltage. Gels were then washed twice in 2.5%
Triton X-100 to remove SDS for 20 min then incubated
for 24 h at 37°C in incubation buffer (50 mM Tris–HCl
pH 7.6 containing 200 mM NaCl, 10 mM CaCl2, 0.02%
BrijW L23, 0.02% NaN3). Gels were stained with Coomassie
Brilliant Blue R solution (Cat. No. B6529; Sigma-Aldrich)
for 1 h then destained in 10% acetic acid for one day
before being scanned with an HP Scanjet 8300 scanner.
Densitometric analysis of lytic zones at 94 and 88 kDa was
performed using ImageJ (freely provided by NIH). The rat
MMP-9 comprises two bands running in the zymography
gels at 94 kDa (glycosylated form) and 88 kDa (intermedi-
ate form) [61].
Immunoblotting
Recombinant MMP-2 and MMP-9 were mixed in
Laemmli sample buffer (Cat. No. 161–0737; Bio-Rad;
Temecula, CA) containing 5% 2-mercaptoethanol and
boiled for 10 min. Samples were loaded into TGX 4-20%
precast gels (Cat. No. 456–1095; Bio-Rad) and subjected to
electrophoresis. Proteins were transferred to Immobilon-FL
polyvinylidene fluoride (PVDF) membranes using a Trans-
Blot Turbo apparatus (Bio-Rad) at 25V for 30 min. Mem-
branes were blocked for 1 h at room temperature with 5%
non-fat milk in Tris-buffered saline (TBS). Membranes
were incubated overnight at 4°C with primary antibodies
against MMP-9 (mouse anti-MMP-9; Cat. No. MS-817-P;
Thermo Scientific) and MMP-2 (rabbit anti-MMP-2; Cat.
No. RPCA-MMP2; EnCor Biotechnology Inc., Gainesville,
FL, USA) diluted 1:1000 in 5% milk in TBST. After washing
with TBST (four times for 5 min each), membranes were
incubated for 1 h at room temperature with goat anti-
mouse IRDye 800CW secondary antibody (Cat. No. 926–
32210; Li-Cor Biotechnology) diluted 1:30,000, and goat
anti-rabbit 680RD antibody (Cat. No. 926–68071) diluted
1:40,000 in 5% milk in TBST. Protein bands were visual-
ized using an Odyssey infrared scanner (Li-Cor Biosci-
ences, Lincoln, NE, USA).
Statistical methods
GraphPad Prism 5 was used for statistical analysis. Statis-
tical significance was assessed by ANOVA followed by
Newman-Keuls corrections for multiple comparisons or
with a Student’s t-test. Linear regression analysis was used
to determine correlation information and significance. Bar
graphs are shown as mean ± SEM. Probability p < 0.05
was considered statistically significant.
Additional file
Additional file 1: Figure S1. MMP-9 activity comparison between
protein G plates and non-coated plates. This experiment was conducted
exactly as described in Materials and Methods with the only exception
being the way the mouse anti-MMP-9 antibody was immobilized to the
plate. Protein G coated plates were obtained from Thermo Fisher
Scientific, and the anti-MMP-9 antibody (Cat No. MS-817-P, Thermo Fisher
Scientific) was immobilized to these plates by incubating at room
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temperature for 2 h in a microplate mixer (see Materials and methods). In
the plates that were not pre-coated with protein G, the anti-MMP-9
antibody was immobilized by passive absorption to Fluotrac 600 high-
binding plates (Greiner Bio-One) overnight at 4°C (1 μg of antibody in
100 μL of phosphate-buffered saline, pH 7.4, per well). Active human
recombinant MMP-9 (0.5, 5 and 10 ng) was added to the plates and
incubated overnight at 4°C. The fluorescence was measured at 24 h after
adding the FRET peptide to the plates (Excitation = 485 nm; Emission =
528 nm). RFUs: relative fluorescence units. **p < 0.01 and ***p < 0.001
with respect to protein G coated plates (Student’s t-test; n = 3 per
concentration of MMP-9).
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